Abbott Laboratories (ABT) 의 후행 P/E는 27.6, 선행 P/E 18.0. 후행 이익수익률은 3.63%, 선행 이익수익률 5.55%. PEG 0.35 (Peter Lynch 저평가 ≤1.0). 그레이엄 넘버는 $50.38.
이 페이지에서 입증된 기준:
SharesGrow 종합 점수: 80/100 5/7 개 기준 통과.
| Year | P/E (TTM) | PEG 비율 | P/B 비율 | P/S 비율 | 배당 수익률 |
|---|---|---|---|---|---|
| 2016 | 40.4 | -0.59 | 2.75 | 2.71 | 2.72% |
| 2017 | 208.6 | -2.91 | 3.22 | 3.63 | 1.86% |
| 2018 | 53.6 | 0.13 | 4.16 | 4.15 | 1.55% |
| 2019 | 41.7 | 0.78 | 4.94 | 4.81 | 1.48% |
| 2020 | 43.2 | 1.99 | 5.92 | 5.61 | 1.32% |
| 2021 | 35.3 | 0.61 | 6.98 | 5.80 | 1.28% |
| 2022 | 27.8 | -36.74 | 5.25 | 4.41 | 1.72% |
| 2023 | 33.4 | -2.05 | 4.94 | 4.76 | 1.86% |
| 2024 | 14.6 | 0.11 | 4.11 | 4.67 | 1.96% |
| 2025 | 33.6 | -0.65 | 4.20 | 4.94 | 1.88% |
| Year | EPS (희석) | 매출 | 순이익 | 순이익률 |
|---|---|---|---|---|
| 2016 | $0.94 | $20.85B | $1.4B | 6.7% |
| 2017 | $0.27 | $27.39B | $477M | 1.7% |
| 2018 | $1.34 | $30.58B | $2.37B | 7.7% |
| 2019 | $2.06 | $31.9B | $3.69B | 11.6% |
| 2020 | $2.50 | $34.61B | $4.5B | 13% |
| 2021 | $3.94 | $43.08B | $7.07B | 16.4% |
| 2022 | $3.91 | $43.65B | $6.93B | 15.9% |
| 2023 | $3.27 | $40.11B | $5.72B | 14.3% |
| 2024 | $7.64 | $41.95B | $13.4B | 31.9% |
| 2025 | $3.72 | $44.33B | $6.52B | 14.7% |
| Year | EPS (평균) | EPS 범위 | 매출 (평균) | 매출 범위 | 애널리스트 수 |
|---|---|---|---|---|---|
| 2026 | $5.65 | $5.47 – $5.76 | $48.33B | $47.96B – $48.51B | 6 |
| 2027 | $6.22 | $6.08 – $6.34 | $52.12B | $51.27B – $52.44B | 6 |
| 2028 | $6.87 | $6.69 – $7.04 | $55.96B | $54.71B – $57.21B | 2 |
| 2029 | $7.59 | $7.52 – $7.63 | $60.3B | $59.85B – $60.54B | 1 |
| 2030 | $8.39 | $8.31 – $8.43 | $64.67B | $64.19B – $64.93B | 1 |
